According to a recent LinkedIn post from Octave Bioscience Inc, real-world use of its MSDA Test for multiple sclerosis (MS) monitoring was highlighted in an oral presentation by Dr. Darin T. Okuda at the AAN 2026 conference. The post notes coverage of the presentation by Multiple Sclerosis News Today, pointing to growing visibility of biomarker-based tools in MS care.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The company’s LinkedIn post suggests that routine monitoring now accounts for 64% of MSDA Test orders, indicating that clinicians may be incorporating the assay into day-to-day disease tracking. It also indicates that MSDA scores are being used to inform discussions about initiating disease-modifying therapies, potentially embedding the test more deeply into treatment decision workflows.
According to the post, Dr. Okuda’s team is exploring use of the MSDA Test during pregnancy and the postpartum period, where objective monitoring options have historically been limited. The post further mentions that Octave offers a financial assistance program aimed at making the test accessible and affordable, which could help reduce adoption barriers among patients.
For investors, the described uptake in routine monitoring and broader clinical use could imply expanding test utilization and a strengthening commercial position in MS diagnostics. If sustained, integration into standard practice and supportive coverage from specialty media may enhance Octave’s competitive standing in biomarker-driven neurology and support longer-term revenue growth potential, subject to reimbursement and clinical validation dynamics.